Figure 4.
Log cardiac T2* MRI (ms)† for deferiprone and deferoxamine groups for the ITT population. (A) The log cardiac T2* MRI over time. Data are shown as means with error bars showing SD. (B) The change in log cardiac T2* MRI from baseline at month 12. Data are shown as geometric means (CV%). A t test was used to calculate the P value. †MRI scans for the assessment of cardiac T2* MRI were performed at screening/baseline, month 6, and month 12 (or early termination), and the images were transmitted to a central laboratory for interpretation. As stipulated in the statistical analysis plan for data normalization, the data were log-transformed before any statistical analyses were performed.

Log cardiac T2* MRI (ms) for deferiprone and deferoxamine groups for the ITT population. (A) The log cardiac T2* MRI over time. Data are shown as means with error bars showing SD. (B) The change in log cardiac T2* MRI from baseline at month 12. Data are shown as geometric means (CV%). A t test was used to calculate the P value. MRI scans for the assessment of cardiac T2* MRI were performed at screening/baseline, month 6, and month 12 (or early termination), and the images were transmitted to a central laboratory for interpretation. As stipulated in the statistical analysis plan for data normalization, the data were log-transformed before any statistical analyses were performed.

Close Modal

or Create an Account

Close Modal
Close Modal